Oppenheimer on Olema Pharmaceuticals (OLMA): "We think there’s more chapters to this story left to unfold"
Tweet Send to a Friend
Oppenheimer analyst Matthew Biegler reiterated an Outperform rating and $48.00 price target on Olema Pharmaceuticals (NASDAQ: OLMA)The analyst commented, "Roche’s ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
